EQUILLIUM, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value
EQUILLIUM, INC. (EQ) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value of $1.33 per share for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-25.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue · last filed 2026-03-25
- EQUILLIUM, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2025 was $1.33, a 137.50% increase from fiscal 2024.
- EQUILLIUM, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2024 was $0.56, a 18.84% decline from fiscal 2023.
- EQUILLIUM, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2023 was $0.69, a 72.29% decline from fiscal 2022.
- EQUILLIUM, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2022 was $2.49, a 36.80% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 10 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 12 month |
|---|---|---|---|
| 2025-12-31 | $1.33 10-K · filed 2026-03-25 | ||
| 2024-12-31 | $0.56 10-K · filed 2026-03-25 | ||
| 2023-12-31 | $0.69 10-K · filed 2025-03-27 | ||
| 2022-12-31 | $2.49 10-K · filed 2024-03-25 | ||
| 2021-12-31 | $3.94 10-K · filed 2023-03-23 | ||
| 2020-12-31 | $3.11 10-K · filed 2022-03-23 | ||
| 2019-12-31 | $4.65 10-K · filed 2021-03-24 | ||
| 2018-12-31 | $5.79 10-K · filed 2020-03-26 | ||
| 2018-09-30 | $5.77 10-Q · filed 2018-11-15 | ||
| 2017-12-31 | $0.00 10-K · filed 2019-03-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Biomea Fusion, Inc. (BMEA) | United States | $0.107B | -3.30 |
| GENELUX Corp (GNLX) | United States | $0.110B | -3.83 |
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| BICYCLE THERAPEUTICS PLC (BCYC) | $0.112B | -1.56 | |
| Quantum Cyber N.V. (QUCY) | $0.113B | ||
| Immuneering Corp (IMRX) | United States | $0.113B | -12.51 |
| ProMIS Neurosciences Inc. (PMN) | $0.102B | ||
| OnKure Therapeutics, Inc. (OKUR) | United States | $0.119B | -3.13 |
| Milestone Pharmaceuticals Inc. (MIST) | $0.098B | -2.00 | |
| CITIUS ONCOLOGY, INC. (CTOR) | United States | $0.097B | -1.49 |